

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCY
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,302		07/18/2003	Karen Stec	ALS-2	7280
	7590 08/04/2006			EXAMINER	
Jeffrey M.			CLAYTOR, DEIRDRE RENEE		
	13 Woodland Drive Lemont, IL 60439			ART UNIT	PAPER NUMBER
				1617	
				DATE MAILED: 08/04/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u></u>	Application No.	Applicant(s)				
	10/622,302	STEC ET AL;				
Office Action Summary	Examiner	Art Unit				
	Renee Claytor	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perions are to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be timed will apply and will expire SIX (6) MONTHS from ute, cause the application to become ABANDONE	1. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 18 2a)□ This action is FINAL. 2b)⊠ The 3)□ Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, pro					
Disposition of Claims						
4) Claim(s) 1-33 is/are pending in the application 4a) Of the above claim(s) is/are withdredship is/are allowed. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-33 are subject to restriction and/or contact of the standard standar	rawn from consideration. or election requirement.					
9) The specification is objected to by the Exami						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Application iority documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	Paper No(s)/Mail Da 8) 5) Notice of Informal Pa 6) Other:	te atent Application (PTO-152)				

DETAILED ACTION

This application claims priority to Provisional Application # 60/398,523 filed on 7/25/2002. Applicant's priority is acknowledged.

Specie Election

This application contains claims directed to the following patentably distinct species of the claimed invention:

- 1. dysfunctions, damage and/or injuries to organs, tissues and/or cells, diseases or conditions, enumerated in claims 1, 18-19.
- therapeutic agents and compounds selected, enumerated in claims 8-17, 24 33.

Each of the above listed species are distinct because they encompass various types of diseases or conditions and unrelated chemical moieties. Further, each recited species acquire a separate status, because they can be classified in different classification. Different classification of species is *prima facie* evidence of undue burden of search.

Accordingly, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant's election should identify **one** dysfunction, damage and/or injuries to organs, tissues and/or cells, disease or condition and **one** therapeutic agent or

Art Unit: 1617

compound. Applicant is also requested to identify which claims are directed to the elected species. Currently claims 1-33 are generic.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added are the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because the above species election requirement is complex, a telephone call to the applicant's agent to request an oral election was not made. See MPEP § 809.02(a).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is 571-272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone

Application/Control Number: 10/622,302

Art Unit: 1617

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER

Page 4